四种钆对比剂不良反应相关因素分析及处理方式

doi:10.12092/j.issn.1009-2501.2018.09.015

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (9): 1056-1062.doi: 10.12092/j.issn.1009-2501.2018.09.015

四种钆对比剂不良反应相关因素分析及处理方式

王军大¹ ，冷静²，杨雅淋²，李艳艳²

¹重庆市中医院放射科；²重庆市中医院药剂科临床药学室，重庆 400021

收稿日期:2018-05-14 修回日期:2018-07-26 出版日期:2018-09-26 发布日期:2018-09-26
通讯作者: 李艳艳，女，硕士，主管中药师，研究方向：临床药学。 Tel: 023-67063730 E-mail: 403819282@qq.com
作者简介:王军大，男，硕士，主治医师，研究方向：放射诊断。 Tel: 023-67063964 E-mail:919734168@qq.com
基金资助:
重庆市科技研发基地能力提升项目（cstc2015pt-kjyfs0019）

Analysis and treatment of adverse reactions associated with four gadolinium contrast agents

WANG Junda ¹, LENG Jing², YANG yalin², LI Yanyan ²

¹ Radiology Department of Chongqing Hospital of Traditional Chinese Medicine;² Clinical Pharmacy Department of Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China

Received:2018-05-14 Revised:2018-07-26 Online:2018-09-26 Published:2018-09-26

摘要/Abstract

摘要：

目的: 探讨四种钆对比剂临床应用中的不良反应（ADR）相关因素及最佳处理方式。方法: 通过比较对比剂特性、患者体质、诊疗类型、对比剂应用情况、增强前基础用药史及发生ADR情况（钆对比剂渗透压、注射后血液中存在形式、排泄途径；患者的年龄、性别、用药剂量、推注方式、增强时间、增强部位；ADR反应时间、严重程度、治疗后转归），综合分析对比剂不良反应发生相关因素，总结对比剂所致急性、晚发性及超晚发性ADR发生率、发生特点及相应临床处理方法。结果: 患者的年龄、注射流速、增强前基础用药、扫描部位是钆对比剂ADR的独立危险因素；线性离子型对比剂发生ADR最高；各系统症状及不同级别ADR严格对症处理；各个系统中均以急性皮肤症状最常见，无需特殊处理痊愈率较高，晚发性或超晚发性患者需给予抗组胺类或糖皮质激素药物治疗；我院随访4年内应用多次大剂量对比剂增强患者均未发现肾源性系统性纤维化（NSF）及齿状核、双肺、胸膜等部位钆沉积征象。结论: 环状对比剂相对发生ADR较少；患者增强前有基础用药史（糖尿病、变应性鼻炎、肿瘤病史）、增强时采取大剂量缓慢推注的体质量轻的中年门诊患者发生急性轻度ADR最高；影像科医务工作者应熟练掌握合理ADR的处理方法，合理使用对比剂能够有效的降低不良反应发生率。

关键词: 钆对比剂, 不良反应, 肾源性系统性纤维化, 磁共振

Abstract:

AIM: To discuss the factors related to the adverse reaction (ADR) in the clinical application of four gadolinium contrast agents and the best way to deal with it. METHODS: The characteristics of the contrast agent, the patient's constitution, the diagnosis and treatment, the application of contrast agent, the history of pre-enhanced basic medication and the occurrence of ADR (gadolinium contrast agent osmotic pressure, the form of the blood in the blood after the injection, the way of excretion, the patient's age, sex, dosage, injection, enhancement time, enhanced site; ADR reaction time, severity, treatment after treatment) were compared to comprehensively analyze the contrast agent adverse reaction factors, summary of contrast agent induced acute, late onset and ultra late onset ADR incidence, occurrence characteristics and corresponding clinical treatment methods. RESULTS: Age, injection velocity, pre- enhanced base medication and scanning site were independent risk factors for gadolinium contrast agent ADR; linear ionic specific agent had the highest ADR; the symptoms of various systems and different levels of ADR were strictly symptomatic; all the systems were most common with acute skin symptoms, without special treatment, high recovery rate, late onset or super. Late onset patients need to be treated with antihistamine or glucocorticoid, and no gadolinium deposits of NSF, dentate nucleus, double lung, and pleura were found in patients who had been enhanced with a number of large dose contrast agents within 4 years of follow-up. CONCLUSION: The relative incidence of ring-shaped contrast agents show less ADR, and the history of basic medication (diabetes, allergic rhinitis, tumor History) before the enhancement, and the middle-aged outpatient with large dose of slow weight and light weight when the enhancement is enhanced, have the highest acute mild ADR. The medical workers in the imaging department should master the reasonable ADR treatment, which can effectively reduce the incidence of adverse reactions.

Key words: gadolinium contrast medium, adverse drug reaction, NSF, MRI

中图分类号:

R817
R9

王军大，冷静，杨雅淋，李艳艳. 四种钆对比剂不良反应相关因素分析及处理方式[J]. 中国临床药理学与治疗学, 2018, 23(9): 1056-1062.

WANG Junda, LENG Jing, YANG yalin, LI Yanyan. Analysis and treatment of adverse reactions associated with four gadolinium contrast agents[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1056-1062.

参考文献

［1］Aran S, Shaqdan KW, Abujudeh HH. Adverse allergic reactions to linear ionic gadolinium-based contrast agents: experience with 194, 400 injections［J］. Clin Radiol, 2015, 70(5):466-475.
［2］王军大, 李艳艳. 8例碘克沙醇静脉注射致不良反应报告分析［J］. 中国药业, 2016, 25(17):79-82.
［3］Heshmatzadeh BA, Prince MR. Preventing allergic reactions to gadolinium-based contrast agents ［J］. Top Magn Reson Imaging, 2016, 25(6):275-279.
［4］孙艳, 郭小超, 黄勇,等. MR钆对比剂全身性不良反应的研究:18540例连续病例分析［J］. 放射学实践, 2016, 31(12):1159-1162.
［5］Kim JA, Blumenfeld JD, Chhabra S, et al. Pancreatic cysts in autosomal dominant polycystic kidney disease: prevalence and association with PKD2 gene mutations［J］. Radiology, 2016, 280(3):762-770.
［6］Takahashi S, Takada A, Saito K, et al. Fatal anaphylaxis associated with the gadolinium-based contrast agent gadoteridol (ProHance).［J］. J Investigational Allergology & Clinical Immunology, 2015, 25(5):366-367.
［7］王军大, 冷静, 李艳艳. 7种静脉注射碘对比剂的合理应用及其不良反应分析［J］. 中国医院药学杂志, 2018,38(6):212-213.
［8］Donald RJ, Mc Donald JS, Kallmes DF,等. 对比增强MRI后颅内钆剂沉积［J］. 国际医学放射学杂志, 2015,38(4):141-144.
［9］Tepetam F M, Ciftaslan N, Oru, et al. Should patients with risk factors be tested for hypersensitivity to contrast media: a prospective study［J］. La Radiologia Medica, 2016, 121(8):660-666.
［10］Rogosnitzky M, Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms［J］. Biometals, 2016, 29(3):365-376.
［11］Costello JR, Kalb B, Martin DR. Incidence and risk factors for gadolinium-based contrast agent immediate reactions［J］. Top Magn Reson Imaging, 2016, 25(6):257-263.
［12］Kanal E, Tweedle MF. Residual or retained gadolinium: practical implications for radiologists and our patients［J］. Radiology, 2015, 275(3):630-634.
［13］Power S, Talbot N, Kucharczyk W,等. MRI对比剂钆布醇的过敏样反应:32991例连续注射病例的前瞻性研究［J］. 国际医学放射学杂志, 2016, 39(6) :163-166.
［14］林义秋, 李莉, 谭文慧. 钆喷酸葡胺对比剂在临床中的不良反应分析［J］. 解放军药学学报, 2015, 31(2):177-178.
［15］叶红梅, 李勇, 张丽群,等. 临床常用磁共振对比剂不良反应观察［J］. 临床合理用药杂志, 2014, 7(12):101-102.
［16］李信华. 47例钆喷酸葡胺注射液不良反应的文献分析［J］. 中南药学, 2016,14(3):333-335.
［17］周庆春. 189例磁共振对比剂钆喷酸普胺致不良反应病例的文献分析［J］. 抗感染药学, 2016, 13(1):118-120.
［18］Radbruch A, Weberling LD, Kieslich PJ, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent ［J］. Radiology, 2015, 275(3):783-791.
［19］Carr TF. Pathophysiology of immediate reactions to injectable gadolinium-based contrast agents［J］. Top Magn Reson Imaging, 2016, 25(6):265-268.
［20］Neeley C, Moritz M, Brown JJ, et al. Acute side effects of three commonly used gadolinium contrast agents in the pediatric population［J］. Br J Radiol, 2016:20160027.
［21］Rosado I A, Doa DI, Cabaas MR, et al. Clinical practice guidelines for diagnosis and management of hypersensitivity reactions to contrast media.［J］. J Investig Allerg Clin Immunol, 2016, 26(3):144-155.
［22］Thomsen HS. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium- 1997-2006-2016. Part 1［J］. Acta Radiologica, 2016, 57(5):515-520.
［23］陈杰, 元刚, 陈孝,等. 临床药师参与1例钆喷酸葡胺致抽搐、昏迷患者救治的药学实践［J］. 今日药学, 2014, 24(5):366-367.
［24］Granata V, Cascella M, Fusco R, et al. Immediate adverse reactions to gadolinium-based MR contrast media: A retrospective analysis on 10,608 examinations［J］. Biomed Res Int, 2016, 2016:1-6.
［25］左应琳, 刘丽, 李文华. 钆喷酸葡胺注射液致罕见过敏性休克1例［J］. 中南药学, 2013, 11(10):799-800.
［26］高志红, 刘丽华, 李杰,等. 一例钆喷酸葡胺注射液致过敏性休克的抢救及护理体会［J］. 临床合理用药杂志, 2015, 8(9):165-165.
［27］Beckett KR, Moriarity AK, Langer JM. Safe use of contrast media: what the radiologist needs to know［J］. Radiographics A Review Publication of the Radiological Society of North America Inc, 2015, 35(6):1738-1750.
［28］王军大, 沈怡, 李映. 钆喷酸葡胺对比剂行冠状动脉CTA诊断及临床安全性分析［J］. 现代医药卫生, 2014,30 (23):3600-3601.
［29］王洋, 纪立伟. 钆特酸葡胺注射液致过敏性休克［J］. 中国药物应用与监测, 2013, 10(5):305-306.

[1]	杜彩凤, 毛宇楠, 高嘉, 王娟, 李小叶, 田俊生, 刘宏奇. 基于1H-NMR代谢组学的绝经期综合征血清代谢标志物研究[J]. 中国临床药理学与治疗学, 2023, 28(9): 961-968.
[2]	李欣宇, 黄鑫. 美洛昔康的临床应用研究现状[J]. 中国临床药理学与治疗学, 2023, 28(2): 189-197.
[3]	王智, 周鑫, 何雪茹, 付裕豪, 荀雪姣, 李颖, 董占军. 哌柏西利治疗乳腺癌的临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 205-213.
[4]	杨梦娇, 袁浩, 郑亚, 王玉平, 郭庆红. 钾离子竞争性酸阻断剂在反流性食管炎中的治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(10): 1190-1196.
[5]	黄伊婷, 沈爱宗. 阿法替尼治疗肺癌的临床疗效与安全性[J]. 中国临床药理学与治疗学, 2021, 26(4): 474-480.
[6]	邢开, 龚金玉, 罗建权. 噻嗪类利尿剂相关不良反应的药物基因组学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(2): 204-212.
[7]	张露, 林良沫, 刘可可, 黄娅敏, 黄行行, 杨永榆, 肖坚. 新型冠状病毒肺炎抗病毒药物的治疗药物监测及药代动力学研究进展[J]. 中国临床药理学与治疗学, 2020, 25(5): 566-575.
[8]	张乃菊, 陈天平, 黄睿, 陈重, 张帆, 孔令提, 夏娟, 刘金春. 利奈唑胺致乳酸酸中毒研究进展[J]. 中国临床药理学与治疗学, 2020, 25(12): 1408-1413.
[9]	盛皓宇, 全斌, 梁曼曼, 吴琼乐, 杨江华. 洛匹那韦/利托那韦治疗新型冠状病毒肺炎不良反应的观察分析[J]. 中国临床药理学与治疗学, 2020, 25(11): 1283-1287.
[10]	王梦芝，卫玉光，黄晓玲. 我院美罗培南合理用药分析[J]. 中国临床药理学与治疗学, 2018, 23(8): 937-941.
[11]	桂华，曹珊珊，赵巧云，王佩红. 克龄蒙联合戈舍瑞林对子宫内膜异位症患者腹腔镜术后血清激素水平的影响[J]. 中国临床药理学与治疗学, 2018, 23(5): 557-560.
[12]	鲁晴，曾庆章，周亚萍，于培明，李浩娜. 基于美国FAERS数据库的依维莫司不良反应分析[J]. 中国临床药理学与治疗学, 2018, 23(5): 547-551.
[13]	徐丽丽，王云甫，全变瑞. 盐酸羟考酮控释片复合窄谱中波紫外线治疗带状疱疹神经痛的疗效[J]. 中国临床药理学与治疗学, 2018, 23(3): 333-336.
[14]	王世彪，王程毅，翁斌，郭晓峰，林海. 无创心输出量监测联合米力农在小儿重症肺炎并心力衰竭中的疗效对比观察及对脑钠肽水平的影响研究[J]. 中国临床药理学与治疗学, 2018, 23(12): 1402-1407.
[15]	周淑珍，高云云，谢静，高孟飞. 米诺环素联合vitapex糊剂治疗持续性根尖周炎的临床研究[J]. 中国临床药理学与治疗学, 2017, 22(2): 170-173.

四种钆对比剂不良反应相关因素分析及处理方式

Analysis and treatment of adverse reactions associated with four gadolinium contrast agents

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价